10x Genomics (TXG) Operating Leases (2020 - 2026)

10x Genomics' Operating Leases history runs 7 years deep, the most recent figure standing at $81.4 million for Q1 2026.

• In Q1 2026, Operating Leases rose 1.64% year-over-year to $81.4 million; the TTM figure through Mar 2026 stood at $81.4 million (up 1.64% YoY), while the FY2025 annual figure was $73.4 million, changed 0.07% from the prior year.
• Operating Leases came in at $81.4 million for Q1 2026 at 10x Genomics, up from $73.4 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $99.0 million in Q2 2022 to a low of $73.3 million in Q4 2024.
• A 5-year average of $85.8 million and a median of $86.1 million in 2022 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases surged 50.21% in 2022 and retreated 13.13% in 2025, its largest moves.
• 10x Genomics' Operating Leases stood at $86.1 million in 2022, then dropped by 2.66% to $83.8 million in 2023, then decreased by 12.55% to $73.3 million in 2024, then increased by 0.07% to $73.4 million in 2025, then grew by 10.92% to $81.4 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $81.4 million, $73.4 million, and $87.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison